ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.850
-0.440 (-13.37%)
At close: Mar 3, 2025, 4:00 PM
2.890
+0.040 (1.40%)
After-hours: Mar 3, 2025, 6:57 PM EST
ImmunityBio Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ImmunityBio stock have an average target of 13.58, with a low estimate of 4.75 and a high estimate of 30. The average target predicts an increase of 376.49% from the current stock price of 2.85.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ImmunityBio stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +952.63% | Mar 3, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +952.63% | Feb 28, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +952.63% | Feb 19, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +952.63% | Feb 14, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +952.63% | Jan 30, 2025 |
Financial Forecast
Revenue This Year
138.94M
from 14.75M
Increased by 842.29%
Revenue Next Year
337.40M
from 138.94M
Increased by 142.84%
EPS This Year
-0.68
from -0.62
EPS Next Year
-0.33
from -0.68
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 179.3M | 496.5M | 1.6B | ||
| Avg | 138.9M | 337.4M | 860.1M | ||
| Low | 107.2M | 185.0M | 449.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,116.0% | 257.3% | 363.5% | ||
| Avg | 842.3% | 142.8% | 154.9% | ||
| Low | 627.1% | 33.2% | 33.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.44 | -0.16 | 0.75 | ||
| Avg | -0.68 | -0.33 | 0.72 | ||
| Low | -1.01 | -0.54 | 0.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.